Dr. Reddy’s has partnered with Citicoline, Ferrer Internacional S.A., Spain, to make Somazina available in India.
Dr. Reddy's Laboratories Ltd announced the launch of Somazina, the innovator brand of Citicoline in the Indian market. Dr. Reddy’s has partnered with the global innovator of Citicoline, Ferrer Internacional S.A., Spain, to make Somazina available in India. This is an important product in the management of stroke and has been used for the treatment of post-stroke patients around the world.
Somazina is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries. Each year about 15 Lakh people suffer from stroke in India.
Cerebral Stroke is the third leading cause of deaths in India, as per the Global Burden of Disease Study 2013. "Stroke is a major cause of disability and death in India. There is a pressing need for novel neuroprotective agents which can salvage brain tissue and optimize the functional outcome." said Dr. Subhash Kaul, renowned senior neurologist from NIMS, Hyderabad.
Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients. “Citicoline is safe to use and may have a beneficial effect in stroke patients. Citicoline is the only drug, that in a number of different clinical stroke trials, has had some neuroprotective effect.” shared Dr. Atul Prasad, Director & Sr. Consultant, BLK Super specialty hospital, Delhi.
Somazina is indicated for improving cognitive function in patients who have suffered from stroke or cerebral infarction, or who have undergone a brain surgery or have suffered from head injuries. Each year about 15 Lakh people suffer from stroke in India.
Cerebral Stroke is the third leading cause of deaths in India, as per the Global Burden of Disease Study 2013. "Stroke is a major cause of disability and death in India. There is a pressing need for novel neuroprotective agents which can salvage brain tissue and optimize the functional outcome." said Dr. Subhash Kaul, renowned senior neurologist from NIMS, Hyderabad.
Citicoline is a widely used neuro-protectant to help accelerate the recovery of these patients. It is used in both ischemic and haemorrhagic strokes, and provides a compelling option to physicians treating stroke patients. “Citicoline is safe to use and may have a beneficial effect in stroke patients. Citicoline is the only drug, that in a number of different clinical stroke trials, has had some neuroprotective effect.” shared Dr. Atul Prasad, Director & Sr. Consultant, BLK Super specialty hospital, Delhi.
No comments:
Post a Comment